CMPS Stock Analysis: Compass Pathways | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.936m USD | 12M Return: 206.9% | US20451W1018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.6M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
COMPASS Pathways plc (NASDAQ: CMPS) is a UK-headquartered biotechnology company developing psychedelic-based therapies for mental health conditions. Its lead investigational product, COMP360, is a synthetic psilocybin formulation currently in Phase III clinical trials for treatment-resistant depression (TRD), and in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. The company operates in both the United Kingdom and the United States, and went public on NASDAQ in September 2020 at a small-cap valuation.
The company was originally incorporated as COMPASS Rx Limited and rebranded to COMPASS Pathways plc in August 2020. Psilocybin is a naturally occurring psychoactive compound that is being investigated by a small group of clinical-stage biotech firms as a potential treatment for psychiatric disorders where existing therapies have shown limited effectiveness, representing an emerging frontier within the broader mental health therapeutics market.
- Phase III COMP360 psilocybin data readout in treatment-resistant depression approaches
- FDA breakthrough therapy designation shapes accelerated regulatory pathway
- Cash burn widens as operating losses outpace no product revenue
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 18.58 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.32 > 3% & CFO -161.1m > Net Income -394.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.6m) vs 12m ago 0.32% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -35.08 > 6 (EBIT TTM -181.8m / Interest Expense TTM 5.18m) |
| A: 0.21 (Total Current Assets 475.7m - Total Current Liabilities 367.3m) / Total Assets 504.6m |
| B: -1.95 (Retained Earnings -985.2m / Total Assets 504.6m) |
| C: -0.46 (EBIT TTM -181.8m / Avg Total Assets 399.0m) |
| D: 0.20 (Book Value of Equity 84.5m / Total Liabilities 420.0m) |
| Altman-Z'' = -7.81 = D |
As of August 27, 2026, the stock is trading at USD 14.61 with a total of 1,744,133 shares traded. Over the past week, the price has changed by +4.28%, over one month by +29.64%, over three months by +19.51% and over the past year by +206.93%.
Current recommended Stop Loss: 13.60 (which is 6.9% or 1.3 ATR below the current price).
Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.
- StrongBuy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.8 | 62.6% |
P/B = 22.6227
Revenue TTM = 0.0 USD
EBIT TTM = -181.8m USD
EBITDA TTM = -181.7m USD
Long Term Debt = 50.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.89m USD (from shortTermDebt, last quarter)
Debt = 58.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.90m
Net Debt = -374.8m USD (calculated: Debt 58.5m - CCE 433.3m)
Enterprise Value = 1.56b USD (1.94b + Debt 58.5m - CCE 433.3m)
Interest Coverage Ratio = -35.08 (Ebit TTM -181.8m / Interest Expense TTM 5.18m)
EV/FCF = -9.69x (Enterprise Value 1.56b / FCF TTM -161.1m)
FCF Yield = -10.32% (FCF TTM -161.1m / Enterprise Value 1.56b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 217k) / Revenue TTM)
Tobins Q-Ratio = 3.09 (Enterprise Value 1.56b / Total Assets 504.6m)
Interest Expense / Debt = 8.85% (Interest Expense 5.18m / Debt 58.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -143.6m (EBIT -181.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.30 (Total Current Assets 475.7m / Total Current Liabilities 367.3m)
Debt / Equity = 0.69 (Debt 58.5m / totalStockholderEquity, last quarter 84.5m)
Debt / EBITDA = 2.06 (negative EBITDA) (Net Debt -374.8m / EBITDA -181.7m)
Debt / FCF = 2.33 (negative FCF - burning cash) (Net Debt -374.8m / FCF TTM -161.1m)
Total Stockholder Equity = 99.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -98.78% (Net Income -394.2m / Total Assets 504.6m)
RoE = -398.2% (Net Income TTM -394.2m / Total Stockholder Equity 99.0m)
RoCE = -121.4% (out of range, set to none) (EBIT -181.8m / Capital Employed (Equity 99.0m + L.T.Debt 50.7m))
RoIC = -103.2% (out of range, set to none) (NOPAT -143.6m / Invested Capital 139.2m)
WACC = 13.45% (E(1.94b)/V(1.99b) * Re(13.65%) + D(58.5m)/V(1.99b) * Rd(8.85%) * (1-Tc(0.21)))
Discount Rate = 13.65% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 89.04 | Cagr: 18.24%
[DCF] Fair Price = unknown (Cash Flow -161.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.19 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.33 | Chg30d=-5.33% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.43 | Chg30d=-43.52% | Revisions=+0% | GrowthEPS=+19.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.43 | Chg30d=-32.10% | Revisions=+25% | GrowthEPS=-0.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=1, down=1)